AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06571513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: During session one of the written exposure therapy intervention, the therapist will provide psychoeducation about PTSD and the rationale for the proposed intervention. Psychoeducation and treatment rationale are scripted to ensure consistency. The therapist will provide the participant with instructions for writing about the same trauma memory (their recent sexual assault) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
Study NCT05585710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral or unilateral mastectomy
Description: Standard of care
Study NCT05585710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue expander
Description: Standard of care
Study NCT05585710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue expander
Description: Standard of care
Study NCT05585710 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acellular dermal matrix
Description: Standard of care
Study NCT05585710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix
Description: Standard of care
Study NCT06571513 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unemotional Writing
Description: During the unemotional writing sessions, the therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did the day before the session from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. The participant will self report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
Study NCT06570187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be administered with an initial dose of 0.2 μg/kg/hour, infusion rate is to be titrated based on response for at least 24 hours.
Study NCT06570187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered as the comparator sedative with the standard treatment of sepsis and septic shock.
Study NCT05320211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed hand orthosis
Description: 3D-printed hand orthoses (intervention) will be compared with custom-fabricated conventional orthoses (control condition at baseline)
Study NCT02129751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrobromide
Description: study drug
Study NCT02129751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo arm
Study NCT06510244 — intervention group
Intervention type: DEVICE
Intervention: EEG EMOTIV
Description: The teeth will be dried with 2x2 gauze; then, Endo Ice will be applied. The patient response will be written on a sheet numbering to choose from 0 to 10, and at the same time, the brain waves will be recorded through EEG.
Study NCT05146635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical Bcg
Description: Patients will receive induction and maintenance BCG after complete TURBT.
Study NCT05146635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical chemotherapy (epirubicin)
Description: Patients will receive induction and maintenance epirubicin after complete TURBT.
Study NCT05226364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber tourniquet
Description: The blood sample is taken with a rubber tourniquet
Study NCT05226364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fabric tourniquet
Description: The blood sample is taken with a fabric tourniquet
Study NCT05226364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without tourniquet
Description: The blood sample is taken without tourniquet
Study NCT05603533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music and video-based group exercise therapy
Description: Each exercise session will last up to 45min. The participants will follow this group exercise therapy twice a week for four months.
Study NCT05071222 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ARTEGENE drug product
Description: Each patient will receive a single intravenous infusion of ARTEGENE drug product at D0.
Study NCT03532373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preference Elicitation tool
Description: A preference elicitation tool for carpal tunnel syndrome
Study NCT04687683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Isometric Relaxation Group
Description: Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions. This stretching exercise will be applied in 5 repetitions for one session.
Study NCT04687683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolytic Stretching Group
Description: Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions for one session.
Study NCT04687683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching Group Group
Description: Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions for one session.
Study NCT05725460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dextrose 5% median nerve hydrodissection
Description: planned to be a good alternative to steroid hydrodissection
Study NCT05725460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dextrose 5% median nerve hydrodissection
Description: planned to be a good alternative to steroid hydrodissection
Study NCT04546295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brushlink application
Description: Brushlink application + Interproximal brush
Study NCT04546295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water-flosser
Description: Water-flosser
Study NCT04546295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interproximal brush
Description: Interproximal brush alone
Study NCT04546295 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interproximal brush
Description: Interproximal brush alone
Study NCT04546295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interproximal brush
Description: Interproximal brush alone
Study NCT04888195 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will complete a set of validated questionnaires (TRSC-C and demographic sheet) before chemotherapy. They also have to complete the same questionnaires (TRSC-C) again within 1 week after the 1st, 2nd, 3rd, 4th , 5th and 6th courses of chemotherapy via telephone interview by our research assistants.
Study NCT05326672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benvitimod Cream
Description: Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
Study NCT04957277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: load modulation
Description: Adding body weight (BW) up to 20% BW and subtracting body weight down to -20% BW
Study NCT04406532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PT-Pal
Description: Participants will be guided through an exercise program in the PT-Pal app. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness.
Study NCT05326672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, applied twice daily for 8 weeks after enrolment.
Study NCT06012266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin tablet
Description: Patients randomized to Group A will start with Dapagliflozin on Visit 1 and take Dapagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Dapagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose:~* participants ≤12 year old: 5mg once daily p.o. (commercially available tablet)~* participants >12 year old: 10mg once daily p.o. (commercially available tablet)
Study NCT06012266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin Tablets
Description: Patients randomized to Group A will start with Empagliflozin on Visit 1 and take Empagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Empagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose: Empagliflozin 10mg once daily p.o. (commercially available tablet)
Study NCT04406532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided exercises
Description: Participants will use the exercise manual to guide the exercise program. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness.
Study NCT05268744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronutrient
Description: Subject will take micronutrient supplement daily for 8 weeks
Study NCT04341987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief Imagery Rehearsal Therapy
Description: Two-sessions of behaviorally-based imagery rehearsal therapy.
Study NCT04341987 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: may include medication treatment or behavioral treatment for nightmares other than imagery rehearsal therapy
Study NCT06101602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching with Floss Band
Description: Floss band involves wrapping a band made of natural rubber around the targeted joint or muscle for 1-3 minutes through active movement. The mechanism behind flossing is thought to have a three-fold effect, compression may stimulate the mechanoreceptors of the underlying fascia layer which causes the hyperemia of the targeted tissue, and leads to increased blood flow.~This intervention was applied in addition to dynamic stretching which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise.
Study NCT06101602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Stretching without Floss Band
Description: In this group, only dynamic stretching was applied which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise.
Study NCT06356441 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AI
Description: An artificial intelligence model predicts the risk and contours of local recurrence for MR images and triages them before radiologists interpret them.
Study NCT04880499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron plus folic acid, vitamin B2, B6, B12, C, and E
Description: A number of 30 subjects are supplemented with iron plus folic acid, vitamin B2, B6, B12, C, and E daily for 60+/-15 days before orthopedic surgery.
Study NCT05910983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar enucleation of the prostate (BipolEP)
Description: Bipolar enucleation of the prostate (BipolEP)
Study NCT05910983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravesical Botox injection
Description: Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
Study NCT05309499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferric carboxymaltose
Description: ferric carboxymaltose is i.v. iron, 121 patiants will be randomised to this group
Study NCT05309499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous sulphate
Description: ferrous sulphate is oral iron, 121patiants will be randomised to this group
Study NCT04984811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efineptakin alfa
Description: 1200 μg/kg NT-I7 administered intramuscularly (IM) once every 6 weeks (Q6W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
Study NCT04984811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg atezolizumab administered intravenously (IV) once every 3 weeks (Q3W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
Study NCT06168929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: SHR4640, 2.5mg\*4 - 10mg\*1
Study NCT06168929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: SHR4640, 10mg\*1 - 2.5mg\*4
Study NCT05067829 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Train of four(TOF)
Description: Train of four(TOF) monitoring after anesthesia induction
Study NCT04564248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website access
Description: website access will be provide to families
Study NCT06225947 — intervention group
Intervention type: DRUG
Intervention: Lemborexant 5 MG
Description: The recommended dosage of Lemborexant(LEM) is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to the maximum recommended dose of 10 mg based on clinical response and tolerability.
Study NCT06120595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REBECCA-assisted intervention 1
Description: The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).
Study NCT06120595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REBECCA-assisted intervention 2
Description: The intervention will include dietary advice, to a psychologist/psychiatrist and/or personal training with a physiotherapist at 'Pusterommet' (SUH).
Study NCT06120595 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard follow-up
Description: Standard follow-up
Study NCT06120595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard follow-up
Description: Standard follow-up
Study NCT06293170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DETECT
Description: DETECT periodically processes real-time data from the corresponding electronic medical record system to screen for a combination of coma, indicated by a Richmond Agitation Sedation Scale (RASS) score of - 4 or - 5 or Glasgow Coma Scale (GCS) score of 6-3, along with manually assessed absence of bilateral pupillary light reflexes. Both findings are considered early indicators of impending ILBF. In case of positive screening results, an automated notification will be sent via the hospital's email server to the corresponding transplant coordinators and intensivists. The email sent aims to prompt clinical assessment of the reported patient and, if necessary, initiate a guideline-based ILBF examination.
Study NCT06293170 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional care
Description: Conventional care
Study NCT06293170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional care
Description: Conventional care
Study NCT05983276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is classified as hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.
Study NCT05983276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is classified as an alkylating agent that is used to treat ovarian cancer.
Study NCT05983276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is classified as a plant alkaloid, a taxane and an antimicrotubule agent.
Study NCT05983276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by killing cancer cells.
Study NCT04555226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph node dissection
Description: Open/minimaly invasive pelvic and para-aortic lymph node dissection
Study NCT04555226 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemoradiation
Description: 1. A point/HCR-CTV D90 ≥80Gy（+20%）~2. Extended-field EBRT: image-positive common iliac lymph nodes with short diameter ≥10mm and/or image-positive para-aortic lymph node~3. Target doses for the image-positive nodes can range from 55 to 60Gy~4. Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~5. CCRT will be completed in 56 days~6. After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) will be performed.
Study NCT04555226 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: 1. A point/HCR-CTV D90 ≥80Gy（+20%）~2. Extended-field EBRT: Pathlogical positive para-aortic lymph node~3. Target doese for pelvic and/or abdomal lymph nodes is usually 45Gy. After operation, the residual lymph node need to be labeled and the target doses for it ranges from 55-60Gy.~4. Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~5. CCRT will be completed in 56 days~6. After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) will be performed.
Study NCT05991518 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injection of IAH0968+Gemcitabine+Cisplatin
Description: Administration of IAH0968 is given once per cycle, with each cycle defined as every 3 weeks.
Study NCT05714657 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Shortened Course Adjuvant Radiotherapy Following TORS
Description: Shortened Course Adjuvant Radiotherapy Following TORS